ArticleThe American journal of gastroenterology2017
Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey.Journal of managed care & specialty pharmacy · 2025Article
- Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden.Harm reduction journal · 2023Article
- Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder in 11 States, 2016-2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States.Journal of health politics, policy and law · 2022Article
- The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.HIV medicine · 2022Article
- Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.Journal of urban health : bulletin of the New York Academy of Medicine · 2021Article
- Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis.Canadian liver journal · 2021Article
- Post-transplant survey to assess patient experiences with donor-derived HCV infection.Transplant infectious disease : an official journal of the Transplantation Society · 2020Article
- Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation.JAMA network open · 2020Article
- Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.Journal of general internal medicine · 2020Observational
- HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.Journal of public health (Oxford, England) · 2019Article
- The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.Liver international : official journal of the International Association for the Study of the Liver · 2019Article
- Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.Gastroenterology · 2019Review
- Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.Current hepatology reports · 2018Article
- Response to Liu et al.The American journal of gastroenterology · 2017Article
- Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.The American journal of gastroenterology · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28374816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.